In Vivo Regional Deposition Measurements for Supporting Model Validation (U01) Clinical Trial Required
Department of Health and Human Services Food and Drug Administration
Type
Financial aid
Posted on:
Application Deadline:
Expired
Reference Number
RFA-FD-23-014
Locally-acting orally inhaled drug products (OIDPs) treat various pulmonary diseases by targeting relevant lung tissue via aerosolized medicine. Regional deposition models are useful for understanding the in vivo performance of OIDPs but require comparator data to support their use for product development purposes. In vivo imaging studies of regional deposition, using techniques such as gamma scintigraphy or single photon emission computed tomography (SPECT) /computed tomography (CT) can provide comparator data for regional deposition models, but the data collected may not be ideally suited to comparison with model predictions. For example, gamma scintigraphy studies produce two-dimensional region specific data while model predictions produce three-dimensional lung generation-level information. The purpose of this funding opportunity announcement is to support the conduct of an in vivo imaging study that uses gamma scintigraphy or SPECT/CT techniques to measure regional lung deposition in human subjects following administration of at least one OIDP with data analysis procedures that are optimized to facilitate a direct comparison with model predictions of branch-level deposition, thereby supporting model validation.
Categories: Consumer Protection, Science and Technology and other Research and Development.
Categories: Consumer Protection, Science and Technology and other Research and Development.
United States